{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:52:17Z","timestamp":1790614337094,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.neuropharm.2012.07.029","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T16:00:47Z","timestamp":1344614447000},"page":"1268-1277","source":"Crossref","is-referenced-by-count":45,"title":["Fibroblast growth factor-20 protects against dopamine neuron loss in\u00a0vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease"],"prefix":"10.1016","volume":"63","author":[{"given":"Isobel J.","family":"Sleeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene L.","family":"Boshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.07.029_bib1","first-page":"25","article-title":"Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease","volume":"12","author":"Anglade","year":"1997","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-5-11","volume":"5","author":"Clarimon","year":"2005","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2990.2003.00487.x","article-title":"Neurotrophins and neurodegeneration","volume":"29","author":"Dawbarn","year":"2003","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1212\/WNL.24.5.431","article-title":"\u201cOn\u2013off\u201d phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine","volume":"24","author":"Fahn","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1098\/rspb.1992.0083","article-title":"Cortical astrocytes activated by basic fibroblast growth factor secrete molecules that stimulate differentiation of mesencephalic dopaminergic neurons","volume":"249","author":"Gaul","year":"1992","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cne.20323","article-title":"Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons","volume":"479","author":"Gonzalez-Hernandez","year":"2004","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/brain\/awf234","article-title":"Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys","volume":"125","author":"Grondin","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3727\/096368908784423256","article-title":"Intraputaminal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys","volume":"17","author":"Grondin","year":"2008","journal-title":"Cell Transplant."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1353-8020(08)70026-9","article-title":"Dopaminergic neurons degenerate by apoptosis in Parkinson's disease","volume":"14","author":"Hirsch","year":"1999","journal-title":"Mov. Disord."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2012.07.029_bib14","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1002\/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F","article-title":"How to improve neuroprotection in Parkinson's disease?","volume":"13","author":"Hirsch","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1471-4159.1997.69010076.x","article-title":"Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system","volume":"69","author":"Hou","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1471-4159.2009.06061.x","article-title":"Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in\u00a0vivo and in\u00a0vitro","volume":"109","author":"Huang","year":"2009","journal-title":"J.\u00a0Neurochem."},{"issue":"12 Suppl. 6","key":"10.1016\/j.neuropharm.2012.07.029_bib17","first-page":"2","article-title":"Complications and limitations of drug therapy for Parkinson's disease","volume":"55","author":"Jankovic","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib18","first-page":"3131","article-title":"Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis","volume":"61","author":"Jeffers","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.2000.3142","article-title":"Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3\u2013p22","volume":"274","author":"Kirikoshi","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer proviudes structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib24","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1046\/j.1460-9568.1998.00324.x","article-title":"Short communication: transforming growth factor-beta mediates the neurotrophic effect of fibroblast growth factor-2 on midbrain dopaminergic neurons","volume":"10","author":"Krieglstein","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1006\/mcne.2002.1134","article-title":"Fibroblast growth factor-2 requires glial-cell-line-derived neurotrophic factor for exerting its neuroprotective actions on glutamate-lesioned hippocampal neurons","volume":"20","author":"Lenhard","year":"2002","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10495-008-0309-3","article-title":"Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps","volume":"14","author":"Levy","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jns.2009.08.025","article-title":"Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease","volume":"25","author":"Li","year":"2003","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1179\/016164103101201472","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in\u00a0vivo","volume":"448","author":"Lindholm","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature05957","article-title":"Clinical neuroprotection in Parksinson's disease \u2013 still waiting for the breakthrough","volume":"289","author":"L\u00f6hle","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1086\/496902","article-title":"High-resolution whole-genome association study of Parkinson disease","volume":"77","author":"Maraganore","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2012.07.029_bib33","first-page":"32","article-title":"Problems with long-term levodopa therapy for Parkinson's disease","volume":"17","author":"Marsden","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0306-4522(93)90339-H","article-title":"Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons \u2013 I. Effects in\u00a0vitro","volume":"56","author":"Mayer","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00439-008-0525-5","article-title":"Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease","volume":"124","author":"Mizuta","year":"2008","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib36","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1523\/JNEUROSCI.2745-06.2006","article-title":"A\u00a0specific survival response in dopamine neurons at most risk in Parkinson's disease","volume":"26","author":"Murase","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib37","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/mds.20573","article-title":"Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra","volume":"20","author":"Noureddine","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jnr.10592","article-title":"FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain","volume":"277","author":"Ohmachi","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/bbrc.2000.3675","article-title":"Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c","volume":"72","author":"Ohmachi","year":"2003","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-8993(92)90855-4","article-title":"Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF","volume":"599","author":"Park","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib41","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1997"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib42","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle","volume":"11","author":"Rosenblad","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/WNR.0b013e328133265b","article-title":"Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population","volume":"18","author":"Satake","year":"2007","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib44","series-title":"Central Nervous System Diseases: Innovative Models of CNS Diseases from Molecule to Therapy","first-page":"131","article-title":"Intervention strategies for degeneration of dopamine neurons in parkinsonism","author":"Schallert","year":"2000"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/exnr.1994.1113","article-title":"Development of dopaminergic neurons in the human mesencephalon and in\u00a0vitro effects of basic fibroblast growth factor treatment","volume":"128","author":"Silani","year":"1994","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0074-7696(08)60149-7","article-title":"Fibroblast growth factors as multifunctional signaling factors","volume":"185","author":"Szebenyi","year":"1999","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","article-title":"Protection and repair of the nigrostriatal dopaminergic system by GDNF in\u00a0vivo","volume":"373","author":"Tomac","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.07.029_bib51","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/77548","article-title":"Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in\u00a0vivo","volume":"6","author":"Tretter","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/421052","article-title":"Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease","volume":"74","author":"van der Walt","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2010.12.013","article-title":"Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease","volume":"228","author":"Voutilainen","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(98)00132-2","article-title":"Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases","volume":"794","author":"Walker","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajhg.2007.09.021","article-title":"Variation in the miRNA-433 binding site of FGF-20 confers risk for Parkinson disease by overexpression of alpha-synuclein","volume":"82","author":"Wang","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib56","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/mds.22723","article-title":"Clinical implications of gene discovery in Parkinson's disease and parkinsonism","volume":"25","author":"Wider","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)91236-A","article-title":"Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K","volume":"526","author":"Yamada","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.029_bib58","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812003656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812003656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:57:21Z","timestamp":1562079441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812003656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0028390812003656"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.07.029","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}